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Abstract
Background Building both strength and endurance has been a challenge in exercise training in the elderly, but dietary sup-
plements hold promise as agents for improving muscle adaptation. Here, we test a formulation of natural products (AX:
astaxanthin, 12 mg and tocotrienol, 10 mg and zinc, 6 mg) with both anti-inflammatory and antioxidant properties in combi-
nation with exercise. We conducted a randomized, double-blind, placebo-controlled study of elderly subjects (65–82 years) on
a daily oral dose with interval walking exercise on an incline treadmill.
Methods Forty-two subjects were fed AX or placebo for 4 months and trained 3 months (3×/week for 40–60 min) with in-
creasing intervals of incline walking. Strength was measured as maximal voluntary force (MVC) in ankle dorsiflexion exercise,
and tibialis anterior muscle size (cross-sectional area, CSA) was determined from magnetic resonance imaging.
Results Greater endurance (exercise time in incline walking, >50%) and distance in 6 min walk (>8%) accompanied training
in both treatments. Increases in MVC by 14.4% (±6.2%, mean ± SEM, P < 0.02, paired t-test), CSA by 2.7% (±1.0%, P < 0.01),
and specific force by 11.6% (MVC/CSA, ±6.0%, P = 0.05) were found with AX treatment, but no change was evident in these
properties with placebo treatment (MVC, 2.9% ± 5.6%; CSA, 0.6% ± 1.2%; MVC/CSA, 2.4 ± 5.7%; P > 0.6 for all).
Conclusions The AX formulation improved muscle strength and CSA in healthy elderly in addition to the elevation in endur-
ance and walking distance found with exercise training alone. Thus, the AX formulation in combination with a functional train-
ing programme uniquely improved muscle strength, endurance, and mobility in the elderly.
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Introduction
Age is characterized by a progressive loss of mobility, with
muscle wasting (sarcopenia) and reduced endurance as key
factors in this exercise intolerance. Exercise training has been
the gold standard for slowing or reversing sarcopenia. Resis-
tance training (RT) has been most effective at treating muscle
wasting,1 while endurance training has the greatest benefits
to exercise intolerance.2,3 However, combining training
modes to treat both declines simultaneously typically yields
a lower response than either mode applied separately.4,5
Recent evidence indicates that dietary supplementsmay lead
to improvements in both strength and endurance, which is a
combination of adaptations that have not been possible with
a traditional training programme alone.5,6 For example, anti-
inflammatory supplements yield greater strength improve-
ments when combined with training in elderly subjects,7 while
antioxidant supplements lead to greater endurance
OR IG INAL ART ICLE
© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 826–833
Published online 26 September 2018 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12318
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any me-
dium, provided the original work is properly cited and is not used for commercial purposes.
improvements.8 Astaxanthin is a natural product with both an-
tioxidant and anti-inflammatory properties9–12 that has been
found to increase strength and endurance. For example,
6 months of feeding in the healthy young resulted in ‘strength
endurance’ gains of 55% as measured by the number of
weighted knee bends completed by the end of the study.13
Muscle adaptations, such as these, in an elderly population
would counter key muscle functional losses that are found with
age.14 Additional benefit would come from combining a dietary
treatment with functional training, which has the potential to
not only reverse muscle wasting and improve exercise intoler-
ance but also to increase mobility with a single intervention.
Astaxanthin accumulates in tissues of animals in the food
chain, such as salmon, that feeds on the marine algae,
Haematococcus pluvialis9 and is estimated to have been
consumed at levels of 6 mg per day in populations with a
salmon-based diet.15 Two factors supplied in the diet, vitamin
E and zinc, also have antioxidant properties, but intake is
often inadequate, especially in the elderly.16 Vitamin E has
the additional benefit of enhancing the antioxidant effect of
astaxanthin in vitro17 and zinc stabilizes SOD1 activity.18 For-
mulating these dietary supplements into a single treatment
offers the possibility of combining or synergizing the benefi-
cial effects of the individual natural compounds with antioxi-
dant and anti-inflammatory properties.
Here, we test a dietary formulation of astaxanthin, vitamin
E, and zinc in combination with exercise training as an
approach to elevate mobility, endurance, and strength
in the elderly.6,8 Previous intervention studies have focused
on astaxanthin alone in young animals and humans, but there
are few studies on the elderly.19 Evidence for the beneficial
impact of AX on old muscle comes from a pilot study in mice,
reported here, that found that AX accumulated in muscle
with feeding and was associated with elevated muscle quality
(specific force) after exercise training on a treadmill. The
approach of this study was to build on this pilot study using
a formulation of dietary factors with antioxidant and
anti-inflammatory properties paired with exercise training.
Our hypothesis was that this astaxanthin-based formulation
in combination with a functionally based exercise training
programme would activate improvements in both endurance
and muscle strength, thereby providing a single approach to
reverse loss of mobility and muscle properties in the elderly.
Methods
Pilot study
Twenty-nine-month-old male mice were treated with either
300 mg/(kg × day) astaxanthin (n = 10, Astareal, Inc. Moses
Lake, WA, USA) or standard chow alone (n = 9). These mice
were very old at the start of training given that 50%
survivorship generally occurs about 28 months of age for this
strain20 (vs. mean life expectancy of 78 years old for humans
in the USA in 201321). The AX dose was determined for mice
by scaling22 from the level found to be effective in rat stud-
ies.23 Exercise training occurred 3×/week on a 20° inclined
treadmill at 10 m/min for 5 min at the start reaching
15 min in the final 4 weeks of training. In vivo muscle force
of the gastrocnemius was measured as the maximum twitch
and tetanic force during electric stimulations (200 Hz for
300 ms) at baseline and at 8 weeks in anaesthetised mice
as described.24 The quadriceps muscle was frozen at the
end of training to determine the level of astaxanthin. The In-
stitutional Animal Care and Use Committee of the University
of Washington Animal approved this experimental protocol.
Human study
This randomized, double-blind, placebo-controlled study was
conducted at the University of Washington Medical Center
and the Fred Hutchison Cancer Research Center. Adults age
65–85 years old were recruited through public lectures,
mailers, posted advertisements, and referrals from prior
studies. To be included in the study, subjects had to be
healthy and not under treatment for serious chronic condi-
tions, ambulatory and able to perform activities of daily living
without assistance, and able to speak and read English
fluently. Exclusion criteria are listed in Table S1. A total of
365 subjects were phone screened; 58 subjects enrolled in
the study and were randomly assigned to groups. Each
subject had a physical examination, resting and exercise
electrocardiogram, and blood testing to ensure that they
were healthy and free from orthopaedic and neuromuscular
problems.
Treatment and dosing
The dietary formulation consisted of astaxanthin (12 mg),
tocotrienol (10 mg), and zinc (6 mg; Astamed, Bellevue, WA)
and was ingested as two capsules per day. The astaxanthin
dose was determined based on safety studies showing that
a dose up to 45 mg per day for 4 weeks is well tolerated with-
out serious side effects.19 Long-term intervention studies
(4 mg/day for 52 weeks25; 12 mg/day26 and 16 mg/day for
12 weeks27) reported no serious adverse side effects. The
12 mg daily dose resulted in significant improvement in
cognitive measurements.26 Two additional components were
included in the formulation because they provide additional
antioxidant benefits and are often ingested below the recom-
mended intakes.16 Tocotrienols (vitamin E) reduce lipid
peroxidation in combination with astaxanthin more than
astaxanthin alone17 and quench reactive oxygen species in
liposomes 40% better than the sum of the two antioxidants
acting alone.28 In addition, zinc stabilizes SOD1 activity.18
Thus, this formulation has more antioxidant protection than
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the individual ingredients as well as supplementing nutrients
that are often ingested below recommended levels.
Randomization and blinding
The subjects were assigned to the two treatment groups by
an individual not associated with the study. A random
number generator provided the assignments. Copies of the
codes were held in separate locations that were not
accessible to the investigators. Thus, the assignment of the
individual subjects to the treatment groups was not known
to the participants or to the investigators until the study
was completed.
Figure 1 shows a chart of the subject flow through the
study. Sixteen subjects dropped out after randomization: 8
for medical reasons unrelated to the treatment, 6 for proto-
col non-adherence, and 2 for personal reasons. Forty-three
subjects (n = 19, placebo and n = 23, astaxanthin formulation)
aged 65–82 years completed the study. The characteristics of
the subjects that completed the study are shown in Table 1.
All participants gave written informed consent consistent
with the Declaration of Helsinki in a project approved
by the University of Washington and Western Institutional
Review Boards.
Exercise training
The 12 week training programme met 3× per week with a
10 min warm-up before and 5–10 min cool down period at
the end of each session. Treadmill training involved walking
at ~1.3 m/sec with periods at a high treadmill incline of
9–12% grade (interval training) separated by periods of low in-
cline walking at 5–7% grade (recovery). Table S2 contains the
time and incline grade (%) used at baseline, at the end of train-
ing, and the overall change with training. The training level was
incremented based on the heart rate (HR) response (HR targets
listed in the succeeding text) as well as relative perceived exer-
tion during the treadmill test. Training progressed in three
steps: (i) familiarization with the treadmill protocol (weeks 1
and 2), which involved 8–10 intervals at the high incline for
~1 min each and recovery for 2 min, (ii) baseline interval train-
ing (weeks 3–7), which involved 1–1.5 min exercise in 8–10 in-
tervals to achieve 70–80% HRmax with 2–3 min of recovery
exercise between intervals, and (iii) ramping up (weeks 8–12),
which involved 1.5–2 min exercise in 10–12 intervals to achieve
80–85% HRmax with 0.5–1.0 min of recovery exercise between
intervals. All exercise training was overseen by an American
College of Sports Medicine certified exercise physiologist at
the Fred Hutchinson Cancer Research Center.
Magnetic resonance imaging
Tibialis anterior (TA) muscle cross-sectional area (CSA) was
determined from magnetic resonance images (Bruker 4.7-T
magnet with Biospin console; Bruker Corporation, Billerica,
MA) acquired as axial plane T1-weighted, 2-D gradient-echo
images collected with the following parameters: 500 ms
repetition time, 2.5 ms echo time, 3 mm slice thickness,
Figure 1 The study flow diagram. Schema of subject progress through the phases of the parallel randomized study of the two treatment groups.
Table 1 Subjects’ characteristics
Placebo AX
Age, year 72.2 ± 5.2 69.1 ± 3.4
F, n 9 13
M, n 10 10
Height, cm 66.6 ± 3.4 66.4 ± 4.1
Weight, kg
Pre 71.1 ± 14.8 73.8 ± 13.4
Post 71.3 ± 14.8 72.4 ± 13.9
BMI
Pre 24.7 ± 3.1 26.3 ± 3.2
Post 25.4 ± 3.1 25.8 ± 3.2
Value are means ± SD. BMI, body mass index.
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1 mm inter-slice interval, 192 × 192 matrix, and number of
excitations = 2. Five slices of each right limb were analysed
with NIH Image software (Image J, version 1.50 e) using
manual planimetry29 to determine the muscle CSA. The
measurements by two independent investigators agreed to
within 2.5% on average.
Single muscle test: isometric ankle dorsiflexion
The TA muscle strength and contractile properties were
determined on the right leg using a custom-built isometric
exercise apparatus, as previously described30 (Figure S1A).
The TA muscle is important in ankle dorsiflexion and repre-
sents a simple system connecting muscle mechanics and
energetics to foot movement30 and is a critical part of walk-
ing mobility. The subject performed a maximal voluntary
contraction (MVC) using ankle dorsiflexion for ~5 sec by
pulling on a strap that secured the foot to a force transducer
platform. Three successive bouts were separated by 5 sec
each (Figure S1B). A test, retest evaluation found no signifi-
cant difference in MVC in two determinations separated by
30 days (0.01 ± 0.04 N, mean ± SEM, n = 24, paired t-test).
The relative standard deviation for the difference scores was
21% (SD of difference/mean × 100).
Statistical analysis
An unpaired Student’s t-test was used to evaluate treatment
vs. placebo in the pilot mouse study. To explore for measure-
ments that change with treatment in the human study, a
paired, 2-tailed t-test (pre-training vs. post-training change)
was used with significance assigned at α = 0.05 (P < 0.05).
No correction for multiple comparisons was used as is consis-
tent with a proof of concept study.31 Data are reported as
means ±SEM in figures and text and ±SD in the tables.
Results
Pilot study
The level of astaxanthin in muscle after the 8 week exer-
cise programme was significantly elevated in the AX
(236.7 ± 123.4 ng/g, n = 4) vs. the placebo (9.2 ± 9.2 ng/g,
n = 6) treatment group. Specific force (maximum twitch
force/muscle cross-sectional area) was significantly greater in
AX vs. placebo-treated mice after training (P < 0.004, Table 2).
Human study
The subjects’ physical characteristics are reported in Table 1.
Figure 2A shows that the time in the interval stage (high %
grade incline walking) was the predominant change with
training (Table S2). The increased interval stage exercise time
demonstrates that the subjects in both treatment groups
could exercise longer (greater time) and at a higher intensity
(higher % grade) after training. Walking distance in the 6 min
walk also significantly improved by ~8% in both groups with
training (Figure 2B, Table S3).
Figure 3 shows the relative change in muscle strength and
size in the two groups with training (Table S4 presents the
absolute changes). A significant change in human muscle
strength, as measured by MVC (Δ14.4 ± Δ6.2% mean ± SEM,
P < 0.02), is shown for the AX treatment group alone. The TA
muscle CSA (Δ2.7 ± Δ1.0%) also only increased in the AX
Figure 2 Changes in endurance (training time) and mobility (walking distance) after 3 months of training in placebo (PL) and astaxanthin formulation
(AX) treated elderly subjects. (A) Change in training time (min) in the recovery (REC) and interval (INT) exercise periods in the training session and (B)
change in distance (m) in the 6 min walk test. Values are mean ± SEM.
*
P < 0.05.
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treatment group (both image analysers found CSA differ-
ences at P < 0.01). The ratio of these measures provides
the muscle specific force (MVC/CSA), which trended to a
higher value (Δ11.6 ± Δ6.1%, P = 0.053) in the AX treatment
group alone. No significant change in muscle properties was
found in the placebo treatment group (MVC,
Δ2.9% ± Δ5.6%; CSA, Δ0.6% ± Δ1.2%; MVC/CSA,
Δ2.4 ± Δ5.7%; P > 0.6 for all).
Discussion
The key findings from this study are that the astaxanthin for-
mulation in combination with functionally based exercise
training improved endurance and walking distance
(Figure 2), as well as elevated muscle strength and size
(sarcopenia) in elderly subjects (Figure 3). Thus, mobility,
endurance, and strength were all improved with a single
training approach in elderly humans. This approach of pairing
a dietary formulation with functionally based training holds
promise as a single mode to reverse key deficits in muscle
and mobility that limit the elderly.14
The pilot study involving exercise training of aged mice on
an incline treadmill provided two results important for the
human study. The first result was that AX accumulated in
the muscle and was significantly above the levels found with
placebo treatment at the end of exercise training. The second
result was that this AX accumulation was associated with sig-
nificantly greater specific force in the AX-treated vs. placebo-
treated muscle after incline training (Table 2), which points to
the biological activity of AX. The human study emulated this
design with the addition of interval training that mixed level
with incline treadmill walking to provide both endurance
and strength training stimuli. Figure 2 shows that total
walking time on the treadmill increased (endurance) due
predominantly to more time in high incline (interval) walking
vs. low incline (recovery) walking after 3 months of training.
The similarity of the response of the two groups indicates
that the antioxidant properties of the AX formulation did
not inhibit the endurance training adaptation as has been
found with other antioxidant treatments in exercise training
interventions.32 Instead, both training groups increased walk-
ing distance in a 6 min test, thereby demonstrating both
greater endurance (treadmill time in interval training) and
mobility (walking distance) with this approach.
Accompanying these functional improvements were adap-
tations in both strength and muscle CSA in the group treated
with the formulation of dietary supplements with antioxidant
and anti-inflammatory properties (astaxanthin, vitamin E, and
zinc) (Figure 3).9,11 The strength gain (14.4%) in the AX formu-
lation group was similar to that found with RT in studies of the
elderly (10–15%,1,7,33) that used isokinetic or isometric
methods to measure MVC. This strength gain was accompa-
nied by an increase in muscle size (2.5%), which indicates that
a greater muscle mass was a part of the gains in strength. Al-
though this CSA gain is smaller than found in RT studies of the
elderly (~10%,1,7,33,34), the muscle size gain was one of a suite
of changes that accompanied the training stimulus with the
AX formulation. This muscle adaptive response has been
found with anti-inflammatory treatments7 and is consistent
with the anti-inflammatory properties reported for AX.10,11
The difference in the strength (14.4%) vs. the CSA change
(2.5%) points to an improved muscle quality with the AX
formulation plus training, as measured by specific force
(MVC/CSA; 11.5%, P = 0.053). Remarkably, this specific force
gain was similar in size to the change found in many RT
studies of the elderly (Figure S2). These results point to
specific force as a key contributor to the strength increases
with the AX formulation treatment in the human study and
to the difference between placebo and AX treatment in the
mice after exercise training (Table 2).
Figure 3 Changes in muscle properties after 3 months of training in AX
formulation and placebo-treated elderly subjects. Changes in maximum
voluntary contraction (MVC), muscle cross-sectional area (CSA), and spe-
cific force (MVC/CSA) are shown. Values are mean ± SEM.
*
P < 0.02,
**P < 0.01, †P = 0.053 for paired 2-tailed t-test.
Table 2 Mouse muscle force, size, and specific force (MVC/mass) after
8 weeks of training with the astaxanthin formulation (AX) or placebo
(PL) supplementation
PL AX
P
(PL vs. AX)
Strength (max. force, mN)
Pre 395 ± 63 366 ± 41 0.32
Post 351 ± 73 406 ± 74 0.12
Muscle size (mass, g)
Post 0.14 ± 0.01 0.13 ± 0.02 0.49
Specific force
(max. force/CSA, N/cm2)
Pre 4.6 ± 1.0 4.7 ± 0.9 0.73
Post 4.0 ± 0.6 5.0 ± 0.6 0.004
Values are mean ± SD: Max. force: maximum twitch force elicited
by electrical stimulation; CSA, cross sectional area; P: α level in a
Student’s t-test. MVC, maximal voluntary force.
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Many factors have been implicated as contributors to a
rise in specific force with training, including neuromuscular,35
muscle architecture,36 and cellular mechanisms.37 Our testing
approach and the observed changes with training and
treatment minimize the impact of several of the factors and
highlight one factor that could raise strength. For example,
direct muscle electrical stimulation (mouse) and ballistic
contractions of the TA muscle38 are designed to recruit all
fibres and thereby reduce the impact of muscle and fibre re-
cruitment on strength measures. Also, the ankle dorsiflexion
exercise protocol primarily activates the TA muscle with little
contribution by other muscles39 indicating a minimal impact
of co-activation of antagonist muscles to the strength mea-
sure. A second factor, muscle architecture (fibre length and
pennation angle), is reported to change strikingly with RT in
old subjects33 but, despite these changes, CSA (or related size
measures) remains the predominant factor determining
MVC.36 The results of these RT studies suggest that other
factors, in addition to muscle architecture, contribute to the
11.5% improvement in specific force found in this study.
Reversal of the denervation that comes with age is a
potential mechanism for increasing specific force with AX
formulation feeding. Such a reversal in neuromuscular func-
tion with RT was demonstrated by two studies: a 4% rise in
MVC relative to an electrically stimulated maximum in
healthy elderly33 and improvement in skeletal muscle inner-
vation reported in obese older adults.40 The neuromuscular
junction (NMJ) is the interface between the muscle and ner-
vous system; it is known to be disrupted by oxidative stress,
leading to degeneration and denervation with age.41 Reduc-
tion of oxidative stress has been shown to improve the NMJ
and specific force in mouse studies.42 The AX formulation is
reported to act as an antioxidant in vitro in rodent models
and in vivo in humans.11 This antioxidant property may re-
duce oxidative stress so that the biosynthetic signals raised
by exercise training can activate rebuilding of degenerative
NMJs with AX treatment. Rejuvenated NMJ’s could permit
activation of more muscle fibres within the TA43 and could
account for the improved specific force of ankle dorsiflexion
found in this study.
Limitations
Three improvements in the experimental design of future
studies would provide insight into the mechanism of action
of astaxanthin beyond this ‘proof of concept’ study. First,
adding an untrained control group to the mouse study would
reveal whether age-related, rather than training-related,
changes were responsible for the lower specific force in the
placebo group after the 8 week experiment. An age-related
decline would point to a mechanism of action that elevates
specific force with astaxanthin feeding and exercise training
in mice as was found in the human study. Second, this study
provides the statistical information needed to power a future
clinical trial to directly test AX formulation treatment vs. pla-
cebo for effectiveness in reversing the strength and muscle
size declines that come with age. Third, a muscle biopsy
would allow a direct test of the mechanism of action of the
AX formulation using biomarkers of inflammation and oxida-
tive stress. Despite the limitations of a ‘proof of concept’
study, the clear responses of the AX formulation group to ex-
ercise training provide a template for interventions designed
to counter sarcopenia, exercise intolerance, and low mobility
in elderly subjects.
Conclusion
Here, we show that functionally based exercise training
combined with a formulation of natural anti-inflammatory
and antioxidant compounds improved muscle strength and
size in elderly subjects more than exercise training alone. This
was done without sacrificing the improvements in walking
distance and endurance that typically accompany endurance
training. These results suggest that the potential for strength
and endurance improvements in elderly muscle is realized
when natural products that promote adaptation are
combined with exercise training incorporating both resis-
tance and aerobic components. The end result is an approach
involving functional exercise and a dietary formulation that
can improve endurance, strength, and function to remedy
the deficits associated with sarcopenia that limit mobility in
the elderly.
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